Currently, a combinatorial approach to synergistically combine 4-1BB therapy with approved tumor-targeted mAbs, such as a combination of Rituximab (anti-CD20 mAbs) and an agonistic 4-1BB antibody, which promotes cytokine production and enhanced tumor clearance [67,75]. The gene discussed is TNFRSF9; the disease is neoplasm.